Commentary on news published in media MKHZN
Document1 page, text from the fileOpen DFM’s file
Agility9 December 2020
Mr. Hassan Abdulrahman Al Serkal Chief Executive Officer
Dubai Financial MarketDubai, UAECommenting on published news
Reference to the above mentioned subject; and in accordance with Chapter IO of the Capital Markets Authority's bylaws of Law No. 7 of the year 20 IO on Disclosure and Transparency as well as its subsequent amendments and resolutions, Agility would like to announce:
Date 9 December 2020Company Name Agility Public Warehousing Company KSCP
Material Information Reference to what was published in the news under "Avigan® Approved for COYID-19 Treatment in Malaysia", Agility
would like to announce that the Malaysian Ministry of Health's Drug Control Authority has approved Avigan® for use in treatment of COYID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy's Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Financial impact Agility cannot assess the financial impact at the moment.
Best Regards,P.O. Box 25418, Safat 13115 KuwaitTel. +965 1809 222, Fax +965 2467 9617Agility Public Warehousing Company K.S.C.PCommercial Registration No.: 28925Paid Capital: KD 202,737,014.100www.agility.com
�_p.ll 13115 ;Li..,J\ 25418 -,,.._,,, +965 2467 9617 v-S"� , +965 1809 222 ._;,;i.,.
t..!l-r--_;, a.,.y,,.11 .:,:,Ll....ll �1 45,_.!,28925 '�J '->)Le,; J.,....
<?,§. ;l..,> 202,737,014.100 't>°_.i.1 JUI ._,...\J Investor Relations Department